IL1B and cardiovascular disorder: Canakinumab, a monoclonal antibody to human IL-1β, has been shown to suppress tumorigenic inflammatory pathways and angiogenesis in certain types of lung cancers, and is currently under investigation for effects in cardiovascular disease [22,23].